[go: up one dir, main page]

WO2005003065A3 - Sulfonamide substituted imidazoquinolines - Google Patents

Sulfonamide substituted imidazoquinolines Download PDF

Info

Publication number
WO2005003065A3
WO2005003065A3 PCT/US2004/020607 US2004020607W WO2005003065A3 WO 2005003065 A3 WO2005003065 A3 WO 2005003065A3 US 2004020607 W US2004020607 W US 2004020607W WO 2005003065 A3 WO2005003065 A3 WO 2005003065A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonamide substituted
useful
substituted imidazoquinolines
compounds
imidazoquinolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/020607
Other languages
French (fr)
Other versions
WO2005003065A2 (en
Inventor
George W Griesgraber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0411916-9A priority Critical patent/BRPI0411916A/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to EP04756208A priority patent/EP1638566A4/en
Priority to CN2004800181459A priority patent/CN1812789B/en
Priority to NZ544330A priority patent/NZ544330A/en
Priority to CA002529322A priority patent/CA2529322A1/en
Priority to MXPA06000144A priority patent/MXPA06000144A/en
Priority to JP2006517711A priority patent/JP2007521280A/en
Priority to AU2004253929A priority patent/AU2004253929A1/en
Publication of WO2005003065A2 publication Critical patent/WO2005003065A2/en
Publication of WO2005003065A3 publication Critical patent/WO2005003065A3/en
Priority to IL172427A priority patent/IL172427A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
PCT/US2004/020607 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines Ceased WO2005003065A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2004253929A AU2004253929A1 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
EP04756208A EP1638566A4 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
CN2004800181459A CN1812789B (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
NZ544330A NZ544330A (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
CA002529322A CA2529322A1 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
BRPI0411916-9A BRPI0411916A (en) 2003-06-27 2004-06-25 sulfonamide-substituted imidazoquinolines
JP2006517711A JP2007521280A (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
MXPA06000144A MXPA06000144A (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines.
IL172427A IL172427A0 (en) 2003-06-27 2005-12-07 Sulfonamide substituted imidazoquinolines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48320003P 2003-06-27 2003-06-27
US60/483,200 2003-06-27

Publications (2)

Publication Number Publication Date
WO2005003065A2 WO2005003065A2 (en) 2005-01-13
WO2005003065A3 true WO2005003065A3 (en) 2005-03-10

Family

ID=33563911

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/020606 Ceased WO2005003064A2 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines
PCT/US2004/020607 Ceased WO2005003065A2 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020606 Ceased WO2005003064A2 (en) 2003-06-27 2004-06-25 Sulfonamide substituted imidazoquinolines

Country Status (16)

Country Link
EP (1) EP1638566A4 (en)
JP (1) JP2007521280A (en)
KR (1) KR20060035637A (en)
CN (1) CN1812789B (en)
AR (2) AR044923A1 (en)
AU (1) AU2004253929A1 (en)
BR (1) BRPI0411916A (en)
CA (1) CA2529322A1 (en)
IL (1) IL172427A0 (en)
MX (1) MXPA06000144A (en)
MY (1) MY157827A (en)
NZ (1) NZ544330A (en)
RU (1) RU2374246C2 (en)
TW (2) TW200514784A (en)
WO (2) WO2005003064A2 (en)
ZA (1) ZA200600769B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
JP2007502288A (en) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
ES2584863T3 (en) 2003-10-03 2016-09-29 3M Innovative Properties Company Pyrazolopyridines and analogues thereof
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
JP2007511527A (en) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo ring compounds
MXPA06005910A (en) 2003-11-25 2006-08-23 3M Innovative Properties Co Substituted imidazo ring systems and methods.
JP2007513165A (en) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Concomitant drugs containing IRM compounds and methods of treatment
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (en) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
WO2006074045A2 (en) * 2004-12-30 2006-07-13 3M Innovative Properties Company Immune response modifier formulations and methods
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EP1922317A4 (en) * 2005-09-09 2009-04-15 Coley Pharm Group Inc Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods
CA2623541A1 (en) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. Method for 1h-imidazo[4,5-c]pyridines and analogs thereof
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
CA2719544C (en) 2008-03-24 2018-01-09 4Sc Ag Substituted imidazoquinolines
PT2606047T (en) 2010-08-17 2017-04-07 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
EP2718292B1 (en) 2011-06-03 2018-03-14 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
CN103582496B (en) 2011-06-03 2016-05-11 3M创新有限公司 There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it
ES2663622T3 (en) 2013-12-17 2018-04-16 Pfizer Inc. Novel 1-pyrrolo [2,3-b] 3,4-disubstituted pyridines and 7H-4,5-disubstituted pyridacins [2,3-c] pyridazines as inhibitors of LRRK2
MX377305B (en) 2015-09-14 2025-03-07 Pfizer NOVEL IMIDAZO[4,5-c]QUINOLINE AND IMIDAZO[4,5-c][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS.
ES2990113T3 (en) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Antibody adjuvant conjugates
BR112019018688A2 (en) 2017-03-10 2020-04-07 Pfizer imidazo [4,5-c] quinoline derivatives as lrrk2 inhibitors
US11279684B2 (en) 2017-09-06 2022-03-22 Bointech SE Substituted imidazoquinolines as agonists of TLR7
WO2019123178A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220119085A (en) * 2019-12-20 2022-08-26 남미 테라퓨틱스, 인크. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful for the treatment of cancer and methods thereof and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1H-imidazopyridine derivative
ES2229790T3 (en) * 1998-10-26 2005-04-16 The Research Foundation Of State University Of New York DERIVATIVES OF LIPOIC ACID AND ITS USE FOR THE TREATMENT OF DISEASES.
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Also Published As

Publication number Publication date
WO2005003065A2 (en) 2005-01-13
TW200511992A (en) 2005-04-01
WO2005003064A2 (en) 2005-01-13
MY157827A (en) 2016-07-29
JP2007521280A (en) 2007-08-02
IL172427A0 (en) 2006-04-10
CN1812789B (en) 2010-07-14
CN1812789A (en) 2006-08-02
WO2005003064A3 (en) 2005-03-31
MXPA06000144A (en) 2006-04-07
EP1638566A4 (en) 2009-03-25
NZ544330A (en) 2009-06-26
KR20060035637A (en) 2006-04-26
AR044923A1 (en) 2005-10-12
RU2374246C2 (en) 2009-11-27
ZA200600769B (en) 2007-05-30
RU2005138915A (en) 2006-06-27
BRPI0411916A (en) 2006-08-15
AU2004253929A1 (en) 2005-01-13
TW200514784A (en) 2005-05-01
CA2529322A1 (en) 2005-01-13
AR044922A1 (en) 2005-10-12
EP1638566A2 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
WO2005003064A3 (en) Sulfonamide substituted imidazoquinolines
WO2002046192A3 (en) Thioether substituted imidazoquinolines
MXPA04005362A (en) Thioether substituted imidazoquinolines.
DK1198233T3 (en) Sulfonamide and sulfamide-substituted imidazoquinolines
EE200100670A (en) Amide substituted imidazoquinolines
HK1047224A1 (en) Urea substituted imidazoquinolines
WO2002046194A3 (en) Substituted imidazopyridines
MXPA04005331A (en) Sulfonamido substituted imidazopyridines.
WO2004028539A3 (en) 1h-imidazo dimers
EP1551372B8 (en) Sequestering subunit and related compositions and methods
WO2004087101A3 (en) Oral formulations of cladribine
WO2005030142A3 (en) Rifalazil formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172427

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2529322

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 544330

Country of ref document: NZ

Ref document number: 12005502306

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004253929

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020057024904

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006517711

Country of ref document: JP

Ref document number: 20048181459

Country of ref document: CN

Ref document number: 3539/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000144

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004756208

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004253929

Country of ref document: AU

Date of ref document: 20040625

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004253929

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/00769

Country of ref document: ZA

Ref document number: 200600769

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005138915

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004756208

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057024904

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0411916

Country of ref document: BR